Briefing
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
Dedicated MRD analysis of post-transplant gilteritinib maintenance in FLT3-ITD AML, expanding the prespecified MRD interaction reported in the 2024 JCO primary paper. Level 2.
- Design: paper
- n: 356
- Assay: FLT3-ITD MRD in the MORPHO trial